. 2017 Aug 11;12(8):e0178763. doi: 10.1371/journal.pone.0178763

Table 3. GVHD tissue-specific immunogenic CMV peptide matches, CMV reactivation before GVHD patients.

Patient-specific process of cross comparison along with the source genes, IC50 values to indicate inverse binding affinity and GVHD organ specific tissue involvement. *Note: Twelve patients with CMV reactivation/infection before GVHD onset exhibited previously identified immunogenic CMV peptide matches with gene expression specific to the tissues affected by GVHD (above); The filter of immunogenicity provides a connection to T cell reactivity shown in vitro to the listed CMV genes in a separate patient population [36]; Patient 79 with muscle/fascia GVHD showed no muscle-specific previously known immunogenic CMV peptide matches but still had three relevant CMV peptide matches expressed in the skeletal muscle (not shown); Tissues in parentheses were also affected by GVHD but without immunogenic matches/expression by patient; Patients 67 and 71 experienced de novo CMV infection; All 13 patients exhibited multiple CMV peptide matches with unknown immunogenicity.

Patient	HLA	Human Gene	IC50 Value	DRP Peptide	CMV Peptide	IC50 Value	CMV Gene	GVHD Organ with Target Gene Expression
10*	HLA-B40:01	TSPYL1	12	SETVALPPL	QENSETVAL	23	UL86	Skin
	HLA-B40:01	HDAC7	27	EEVEAVTAL	AEREAVTAL	20	UL49
	HLA-B08:01	APEH	487	NRRSALYSV	MWKNRRSAL	11	UL37
	HLA-B08:01	APEH	487	NRRSALYSV	WKNRRSALL	274	UL37
27*	HLA-C03:04	IL22RA1	16	IVHPTPTPL	SSTPTPTPL	42	UL82	Skin
	HLA-A02:01	TECR	28	ALFSLVVFT	YLFSLVVLV	3	US3
	HLA-A02:01	TECR	28	ALFSLVVFT	LVYLFSLVV	442	US3
	HLA-C03:04	WNK1	41	ITAAATAPV	TTAAATATV	199	UL105
45*	HLA-A68:02	PPP1R15A	149	SSAAAAAAL	TAAAAAAAA	58	IRS1,TRS1	Skin & Vagina
	HLA-A68:02				ATAAAAAAA	59	IRS1,TRS1
	HLA-A68:02				DAAAAAAPT	286	IRS1
	HLA-A68:02				SVSSSAAAA	376	UL105
	HLA-A68:02				SASAAAAAA	469	UL105
	HLA-A68:02				DATAAAAAA	470	IRS1,TRS1
	HLA-A68:02	MUC21	106	ESSTTSSGA	TTYTTSSGA	24	UL86	Vagina
	HLA-A68:02	MUC21	106	ESSTTSSGA	YTTSSGAKI	140	UL86
	HLA-A68:02	HOXD13	352	AAAAAAAGA	TAAAAAAAA	58	IRS1,TRS1
	HLA-A68:02				ATAAAAAAA	59	IRS1,TRS1
	HLA-A68:02				DAAAAAAPT	286	IRS1
	HLA-A68:02				SASAAAAAA	469	UL105
	HLA-A68:02				DATAAAAAA	470	IRS1,TRS1
47*	HLA-B07:05	MUC17	52	TPVSHTLVA	TPVSHTQPL	8	UL150	GI
47*	HLA-A30:02	CARS2	343	SPASLSSLY	YFDSLSSLY	173	UL29,UL28	GI
48*	HLA-A31:01	PLXND1	200	LFVFCTKSR	NLFVFCTER	58	UL34	GI (Skin & Liver)
48*	HLA-A31:01	PLXND1	307	VALFVFCTK	NLFVFCTER	58	UL34	GI (Skin & Liver)
67*	HLA-A02:01	FGFR4	20	RLLLALLGV	VLLLALLLL	209	US29	GI, Lung (Skin)
67*	HLA-A02:01	FGFR4	165	LLLALLGVL	VLLLALLLL	209	US29	GI, Lung (Skin)
68*	HLA-A31:01	ALCAM	188	TYTLTAVRR	ASLLTAVRR	68	IRS1,TRS1	GI, Liver (Skin)
70*	HLA-C07:02	LCN2	122	SYPGLPSYL	MRPGLPSYL	50	UL75	GI
	HLA-B35:01	SERPINB4	97	EAAAATAVL	CAAAAATAA	393	UL105
	HLA-A03:01	FYCO1	488	RASLKRLVK	STLKRLVKK	83	UL69
71*	HLA-C03:03	PPP1R15A	19	SSAAAAAAL	AAAAAAPTV	48	IRS1,TRS1	Skin
	HLA-C03:03				AAAAAAAAA	343	IRS1,TRS1
	HLA-C03:03				TAAAAAAAA	389	IRS1,TRS1
	HLA-C03:03				SASAAAAAA	421	UL105
	HLA-A30:02	CARS2	343	SPASLSSLY	YFDSLSSLY	173	UL29,UL28
76*	HLA-A03:01	ZZEF1	119	SVLSELLKK	SVLSELLNK	91	UL54	GI
76*	HLA-B27:05	MUC4	414	TRHATSLPV	YQLRHATSL	473	US29	GI
84*	HLA-A02:01	FGFR4	20	RLLLALLGV	VLLLALLLL	209	US29	GI (Skin)
	HLA-A02:01	FGFR4	165	LLLALLGVL	VLLLALLLL	209	US29
	HLA-C02:02	MUC17	270	TSMPVSTTV	ISYPVSTTV	215	UL75
	HLA-B27:05	MUC4	414	TRHATSLPV	YQLRHATSL	473	US29
90*	HLA-A02:01	PELP1	78	LLALLLAPT	LLALLLLEL	38	US29	Skin & GI
	HLA-A02:01	PELP1	78	LLALLLAPT	VLLLALLLL	209	US29
	HLA-A02:01	AHSA1	321	KTLFLAVQV	ELFLAVQFV	145	UL86
	HLA-C03:03	TCF7L1	107	AAASSSGQM	AAASSSSAV	27	UL48	GI
	HLA-C03:03	TCF7L1	107	AAASSSGQM	IAAASSSSA	220	UL48
	HLA-A03:02	ZZEF1	325	SVLSELLKK	SVLSELLNK	185	UL54
	HLA-C03:03	PLEKHA6	385	AASSSLRRL	FGGAASSSL	71	UL122